Previous 10 | Next 10 |
Virax Biolabs Group ( VRAX ) +40% on launch of real-time PCR test for monkeypox in Europe. 36Kr Holdings ( KRKR ) +14% . InflaRx ( IFRX ) +12% Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Crit...
- At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) was + 1.52 cm/yr (p= 0.02, n=11 ) and the responder rate was 64% in children 5 years and older 1 - Infigratinib...
BridgeBio Pharma ( NASDAQ: BBIO ) and Sentynl Therapeutics' said a committee of the European Medicines Agency (EMA) recommended approval under exceptional circumstances of their therapy Nulibry to treat patients with molybdenum cofactor deficiency ...
BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A PR Newswire - CHMP recommendation for approval of NULIBRY in the European Union (EU) for the treatment of patients with molybdenum...
PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced its founding affiliation with Bakar Labs, the incubator at UC Berkeley’s Bakar BioEng...
PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced a new collaboration with Baylor College of Medicine to identify and translate cutting-edge...
BridgeBio Pharma (NASDAQ:BBIO) said positive phase 1 data of BBP-711 in healthy volunteers supports developing the therapy for patients with primary hyperoxaluria type 1 (PH1) and recurrent kidney stone formers. PH1 is a rare disorder that mainly affects kidneys and is caused due to the build...
– BBP-711 led to near complete inhibition of glycolate oxidase throughout the dosing period and greater than 10-fold increases in plasma glycolate, suggesting it has the potential to be both a best-in-class therapy and the first oral therapy for PH1 and recurrent kidney stone f...
Gainers:Scholar Rock Holding (SRRK) +6%. Science 37 Holdings (SNCE) +6%. Arcimoto (FUV) +5%. Hyzon Motors (HYZN) +4%. SoundHound (SOUN) +4%. Losers: Guardant Health (GH) -5%. CymaBay Therapeutics (CBAY) -5%. Polestar Automotive Holding (PSNY) -5%. Adagio Therapeutics, (...
The shares of BridgeBio Pharma (NASDAQ:BBIO) traded higher in the morning hours Wednesday after the clinical-stage biotech announced encouraging data from the first two subjects who received the company’s Canavan disease candidate BP-812 in a Phase 1/2 clinical trial. An ultra-rare and...
News, Short Squeeze, Breakout and More Instantly...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...